期刊
INTESTINAL RESEARCH
卷 17, 期 3, 页码 311-316出版社
KOREAN ASSOC STUDY INTESTINAL DISEASES
DOI: 10.5217/ir.2019.00043
关键词
Mucosal healing Hematopoietic stem cell; Mesenchymal stem cell; Intestinal stem cell; Organoids
资金
- Ministry of Education, Culture, Sports, Science and Technology/Japan Society for the Promotion of Science (MEXT/JSPS) KAKENHI [26221307, 16H05284, 226221307, 18K07934, 18K15743, 18K15774]
- Research Center Network Program for Realization of Regenerative Medicine from Japan Agency for Medical Research and Development (AMED) [16bm0304001h0004, 17BM03041H0005, 18bm03041h0006, 19bm0304001h0007]
- Grants-in-Aid for Scientific Research [18K07934, 18K15743, 16H05284, 18K15774, 26221307] Funding Source: KAKEN
Inflammatory bowel disease (IBD) is an idiopathic, multi-etiological disease characterized by inflammation and mucosal destruction of the gastrointestinal tract. Despite the remarkable advance in immunomodulating therapies, there still remains a certain population of patients who are refractory to conventional as well as biologic therapies and fail to achieve mucosal healing. To improve the prognosis of those patients, at least 2 types of stem cells have been tested for their potential therapeutic use. Transplantation of hematopoietic stem cells or mesenchymal stem cells have been tested in several clinical studies, but their beneficial effect still remains controversial. In this review, we would like to overview the recent clinical challenges of stem cell-based therapies in IBD and also introduce our new therapeutic plan of intestinal stem cell transplantation for IBD, based on our ex vivo intestinal organoid culture technique.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据